利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

49 条记录 (耗时 0.032 秒)

    Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine
    4.
    发明申请
    Treatment of CNS Disorders With trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine 有权
    用反式4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理中枢神经系统疾病

    公开(公告)号：US20090292026A1

    公开(公告)日：2009-11-26

    申请号：US12538583

    申请日：2009-08-10

    申请人： Thomas P. Jerussi ,  Qun Kevin Fang ,  Mark G. Currie

    发明人： Thomas P. Jerussi ,  Qun Kevin Fang ,  Mark G. Currie

    IPC分类号： A61K31/135 ,  A61P25/00

    CPC分类号： C07C211/42 ,  C07B2200/07 ,  C07C2602/10 ,  C07C2602/28

    摘要： Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

    摘要翻译： 用（1R，4S） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺处理CNS病症; 和（1S，4R） - 反式-4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺。 还公开了制备4-（3,4-二氯苯基）-1,2,3,4-四氢-1-萘胺的方法。 该方法包括制备N- [4-（3,4-二氯苯基）-1,2,3,4-四氢萘-1-基]甲酰胺的全部四种异构体，它们也是有用的。

    Tramadol analogs and uses thereof
    6.
    发明授权
    Tramadol analogs and uses thereof 有权
    曲马多类似物及其用途

    公开(公告)号：US06780891B2

    公开(公告)日：2004-08-24

    申请号：US10308878

    申请日：2002-12-02

    申请人： Chris Hugh Senanayake ,  Thomas P. Jerussi ,  Paul T. Grover ,  Qun Kevin Fang ,  Mark Currie

    发明人： Chris Hugh Senanayake ,  Thomas P. Jerussi ,  Paul T. Grover ,  Qun Kevin Fang ,  Mark Currie

    IPC分类号： C07C21101

    CPC分类号： C07C217/74 ,  C07C217/52 ,  C07C255/59 ,  C07C2601/02 ,  C07C2601/14

    摘要： Compounds of formula I are effective in treating disorders modulated by opiate receptor activity and/or monoamine activity. In formula I, R1 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl; R2 is selected from hydrogen, hydroxy, cyano, haloalkyl, glycosyl, SO2R5, and OR5; R3 and R4 are independently selected from hydrogen and lower alkyl, or R3 and R4 taken together with nitrogen form a five- or six-membered heterocyclic or substituted heterocyclic ring; and R5 is selected from alkyl, aryl, alkylaryl, substituted alkyl, substituted aryl, and substituted alkylaryl.

    摘要翻译： 式I化合物在治疗由阿片剂受体活性和/或单胺活性调节的病症中是有效的。在式I中，R 1选自烷基，芳基，烷基芳基，取代的烷基，取代的芳基和取代的烷基芳基; R 2选自氢，羟基，氰基，卤代烷基，糖基，SO 2 R 5和OR 5; R 3和R 4独立地选自氢和低级烷基，或R 3和R 4与氮一起形成五元或六元杂环或取代的杂环; R 5选自烷基，芳基，烷基芳基，取代的烷基，取代的芳基和取代的烷基芳基。

    Compositions of optically pure (+) norcisapride
    7.
    发明授权
    Compositions of optically pure (+) norcisapride 失效
    光学纯（+）诺西沙必利组合物

    公开(公告)号：US06632827B2

    公开(公告)日：2003-10-14

    申请号：US09809165

    申请日：2001-03-16

    申请人： John R. McCullough ,  Thomas P. Jerussi

    发明人： John R. McCullough ,  Thomas P. Jerussi

    IPC分类号： A61K31445

    CPC分类号： A61K31/495 ,  A61K31/4468 ,  A61K2300/00

    摘要： Compositions and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

    摘要翻译： 公开了使用去甲西沙必利的光学纯（+）异构体的组合物和方法。 令人惊讶地发现，该化合物是用于治疗中枢神经系统疾病的有效药物。 化合物（+）诺西沙必利还被发现是一种有效的止吐剂。 最后，诺西沙必利的（+）异构体也避免了某些不良副作用和某些药物不良反应。

    Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
    8.
    发明授权
    Methods for the treatment of neuroleptic and related disorders using sertindole derivatives 失效
    使用sertindole衍生物治疗精神病和相关疾病的方法

    公开(公告)号：US06489341B1

    公开(公告)日：2002-12-03

    申请号：US09580492

    申请日：2000-05-30

    申请人： Thomas P. Jerussi

    发明人： Thomas P. Jerussi

    IPC分类号： A61K31454

    CPC分类号： A61K31/454 ,  A61K31/445 ,  A61K31/00 ,  A61K2300/00

    摘要： The invention relates to methods of administering pharmaceutical compositions and dosage forms comprising the sertindole derivatives nor-sertindole, 5-oxo-sertindole, dehydro-sertindole, and dehydro-nor-sertindol. The methods of the invention are directed to the treatment and prevention of neuroleptic and related disorders such as, psychotic disorders, depression, anxiety, substance addiction, memory impairment and pain.

    摘要翻译： 本发明涉及给药药物组合物和剂型的方法，所述药物组合物和剂型包含sertindole衍生物nor-sertindole，5-氧代 - 三吲哚，脱氢 - sertindole和脱氢 - nor- sertindol。 本发明的方法涉及治疗和预防精神病和相关疾病，例如精神障碍，抑郁，焦虑，物质成瘾，记忆障碍和疼痛。

    Derivatives of (−)-venlafaxine and methods of preparing and using the same
    9.
    发明授权
    Derivatives of (−)-venlafaxine and methods of preparing and using the same 有权
    （ - ） - 文拉法辛的衍生物及其制备和使用方法

    公开(公告)号：US06342533B1

    公开(公告)日：2002-01-29

    申请号：US09450690

    申请日：1999-11-30

    申请人： Thomas P. Jerussi ,  Chrisantha H. Senanayake

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake

    IPC分类号： A61K31135

    CPC分类号： C07C217/74 ,  A61K31/137 ,  A61K31/277 ,  C07B2200/07 ,  C07C213/00 ,  C07C213/02 ,  C07C215/64 ,  C07C2601/14

    摘要： Methods of preparing, and compositions comprising, derivatives of (−)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

    摘要翻译： 公开了制备方法和包含（ - ） - 文拉法辛的衍生物的组合物。 还公开了治疗和预防疾病和病症的方法，包括但不限于情感障碍如抑郁，双相和躁狂症，注意力缺陷障碍，具有多动症的注意缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖症和 体重增加，失禁，痴呆和相关疾病。